Patent ID: 6923968

Claim:
A method for reducing the occurrence of hypercalcemia or osteosarcoma in a patient, wherein said patient has osteoporosis and has received administration of, or is being administered, cyclase activating parathyroid hormone (CAP) or analogues thereof, said method comprising also administering a cyclase inhibiting parathyroid hormone peptide (CIP) to said patient in a therapeutically effective, but non-toxic amount, where said CIP comprises a contiguous portion of PTH having amino acid sequence set forth in SEQ ID NO:5 (PTH 1-84 ), said portion having an N-terminal amino acid residue starting at any position spanning from position 2 through position 34 of the PTH 1-84 , and a C-terminal amino acid residue ending at position 84 of the PTH 1-84 , or a conservatively substituted variant thereof exhibiting parathyroid hormone (PTH) antagonist activity.